Secondary Consequences of β Cell Inexcitability: Identification and Prevention in a Murine Model of KATP-Induced Neonatal Diabetes Mellitus

被引:79
作者
Remedi, Maria Sara [1 ]
Kurata, Harley T. [1 ]
Scott, Alexis [1 ]
Wunderlich, F. Thomas [2 ,3 ]
Rother, Eva [2 ,3 ]
Kleinridders, Andre [2 ,3 ]
Tong, Ailing [1 ]
Bruening, Jens C. [2 ,3 ]
Koster, Joseph C. [1 ]
Nichols, Colin G. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA
[2] Univ Cologne, Inst Genet, CMMC, D-50674 Cologne, Germany
[3] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50674 Cologne, Germany
关键词
KCNJ11 ACTIVATING MUTATIONS; DEVELOPMENTAL DELAY; KIR6.2; CHANNELS; SULFONYLUREA; SENSITIVITY; GLUCAGON; INSULIN; DYSFUNCTION; MINIREVIEW;
D O I
10.1016/j.cmet.2008.12.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
ATP-insensitive K-ATP channel mutations cause neonatal diabetes mellitus (NDM). To explore the mechanistic etiology, we generated transgenic mice carrying an ATP-insensitive mutant K-ATP channel subunit. Constitutive expression in pancreatic beta cells caused neonatal hyperglycemia and progression to severe diabetes and growth retardation, with loss of islet insulin content and beta cell architecture. Tamoxifen-induced expression in adult beta cells led to diabetes within 2 weeks, with similar secondary consequences. Diabetes was prevented by transplantation of normal islets under the kidney capsule. Moreover, the endogenous islets maintained normal insulin content and secretion in response to sulfonylureas, but not glucose, consistent with reduced ATP sensitivity of beta cell K-ATP channels. In NDM, transfer to sulfonylurea therapy is less effective in older patients. This may stem from poor glycemic control or lack of insulin because glibenclamide treatment prior to tamoxifen induction prevented diabetes and secondary complications in mice but failed to halt disease progression after diabetes had developed.
引用
收藏
页码:140 / 151
页数:12
相关论文
共 34 条
  • [21] KATP channels as molecular sensors of cellular metabolism
    Nichols, CG
    [J]. NATURE, 2006, 440 (7083) : 470 - 476
  • [22] PEARSON ER, 2006, NEW ENGL J MED, V355, P507
  • [23] Minireview:: Secondary β-cell failure in type 2 diabetes -: A convergence of glucotoxicity and lipotoxicity
    Poitout, V
    Robertson, RP
    [J]. ENDOCRINOLOGY, 2002, 143 (02) : 339 - 342
  • [24] Neonatal diabetes mellitus:: a disease linked to multiple mechanisms
    Polak, Michel
    Cave, Helene
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2007, 2 (1)
  • [25] A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome
    Proks, P
    Girard, C
    Haider, S
    Gloyn, AL
    Hattersley, AT
    Sansom, MSP
    Ashcroft, FM
    [J]. EMBO REPORTS, 2005, 6 (05) : 470 - 475
  • [26] A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes
    Proks, Peter
    Arnold, Amanda L.
    Bruining, Jan
    Girard, Christophe
    Flanagan, Sarah E.
    Larkin, Brian
    Colclough, Kevin
    Hattersley, Andrew T.
    Ashcroft, Frances M.
    Ellard, Sian
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (11) : 1793 - 1800
  • [27] Involvement of the N-terminus of Kir6.2 in coupling to the sulphonylurea receptor
    Reimann, F
    Tucker, SJ
    Proks, P
    Ashcroft, FM
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1999, 518 (02): : 325 - 336
  • [28] Diet-induced glucose intolerance in mice with decreased β-cell ATP-sensitive K+ channels
    Remedi, MS
    Koster, JC
    Markova, K
    Seino, S
    Miki, T
    Patton, BL
    McDaniel, ML
    Nichols, CG
    [J]. DIABETES, 2004, 53 (12) : 3159 - 3167
  • [29] KATP-channels and glucose-regulated glucagon secretion
    Rorsman, Patrik
    Salehi, S. Albert
    Abdulkader, Fernando
    Braun, Matthias
    MacDonald, Patrick E.
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2008, 19 (08) : 277 - 284
  • [30] Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2 -: Patient characteristics and initial response to sulfonylurea therapy
    Sagen, JV
    Ræder, H
    Hathout, E
    Shehadeh, N
    Gudmundsson, K
    Bævre, H
    Abuelo, D
    Phornphutkul, C
    Molnes, J
    Bell, GI
    Gloyn, AL
    Hattersley, AT
    Molven, A
    Sovik, O
    Njolstad, PR
    [J]. DIABETES, 2004, 53 (10) : 2713 - 2718